[go: up one dir, main page]

IL125711A0 - Human metabotropic glutamate receptor - Google Patents

Human metabotropic glutamate receptor

Info

Publication number
IL125711A0
IL125711A0 IL12571197A IL12571197A IL125711A0 IL 125711 A0 IL125711 A0 IL 125711A0 IL 12571197 A IL12571197 A IL 12571197A IL 12571197 A IL12571197 A IL 12571197A IL 125711 A0 IL125711 A0 IL 125711A0
Authority
IL
Israel
Prior art keywords
mglur
metabotropic glutamate
glutamate receptor
human metabotropic
modulate
Prior art date
Application number
IL12571197A
Other languages
English (en)
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Publication of IL125711A0 publication Critical patent/IL125711A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL12571197A 1996-02-21 1997-02-20 Human metabotropic glutamate receptor IL125711A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/604,298 US6084084A (en) 1996-02-21 1996-02-21 Human metabotropic glutamate receptor
PCT/US1997/009025 WO1997048724A2 (fr) 1996-02-21 1997-02-20 Nouveau recepteur humain du glutamate metabotrope

Publications (1)

Publication Number Publication Date
IL125711A0 true IL125711A0 (en) 1999-04-11

Family

ID=24419059

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12571197A IL125711A0 (en) 1996-02-21 1997-02-20 Human metabotropic glutamate receptor
IL125711A IL125711A (en) 1996-02-21 1998-08-09 Human metabotropic glutamate receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL125711A IL125711A (en) 1996-02-21 1998-08-09 Human metabotropic glutamate receptor

Country Status (10)

Country Link
US (3) US6084084A (fr)
EP (1) EP0882065B1 (fr)
JP (1) JP2000506392A (fr)
AT (1) ATE369385T1 (fr)
AU (1) AU719841B2 (fr)
CA (1) CA2246751A1 (fr)
DE (1) DE69737990T2 (fr)
ES (1) ES2292193T3 (fr)
IL (2) IL125711A0 (fr)
WO (1) WO1997048724A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521297A (en) * 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
AU710128B2 (en) * 1995-07-26 1999-09-16 Astrazeneca Ab Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
US6221609B1 (en) 1996-07-03 2001-04-24 Eli Lilly And Company Isolate nucleic acid encoding human MGLUR8
WO1999051641A1 (fr) * 1998-04-03 1999-10-14 Nps Pharmaceuticals, Inc. Recepteurs d'hybridation de proteine g et recepteurs gabab chimeres
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
EP1105734A4 (fr) * 1998-08-18 2005-04-13 Univ Johns Hopkins Med Proteines a interaction de la famille homer
EP1662255A3 (fr) * 1998-08-18 2006-09-13 The Johns Hopkins University School Of Medicine Protéines interagissant avec Homer
EP2311944A1 (fr) * 1998-08-31 2011-04-20 The Provost, Fellows and Scholars of the College Of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Polypeptides et polynucleotides issus du staphylocoque négatif quant à la coagulase
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US6620850B2 (en) 2001-09-19 2003-09-16 University Of Florida Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
US20050233321A1 (en) * 2001-12-20 2005-10-20 Hess John W Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
CA2472472A1 (fr) * 2002-01-10 2003-07-24 Osteotrophin Llc Traitement des affections osseuses avec des medicaments anabolisants du squelette
US20060252922A1 (en) * 2002-12-04 2006-11-09 Macina Roberto A Compositions, splice variants and methods relating to colon specific genes and proteins
US20050186658A1 (en) * 2003-10-17 2005-08-25 Nps Pharmaceuticals, Inc. Chimeric metabotropic glutamate receptors and uses thereof
WO2005073730A1 (fr) * 2004-01-31 2005-08-11 Bayer Healthcare Ag Diagnostic et traitement de maladies associees au recepteur du glutamate metabotropique 8 (mglur8) humain
US7777016B2 (en) * 2004-10-14 2010-08-17 Carnegie Institution Of Washington Neurotransmitter sensors and methods of using the same
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
US8889950B2 (en) * 2006-07-28 2014-11-18 The George Washington University Repression of AtGLR3.2 increases plant biomass
US7424876B2 (en) * 2006-10-06 2008-09-16 Ford Global Technologies, Llc Pushrod engine with multiple independent lash adjusters for each pushrod
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CN103342695B (zh) 2007-09-14 2015-04-22 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
CA2707309A1 (fr) 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Nouveaux polypeptides du recepteur de l'addl, polynucleotides et cellules hotes pour une production recombinante
CN102159713A (zh) * 2008-05-20 2011-08-17 Eos神经科学公司 用于递送光敏蛋白的载体和使用方法
CN102143955B (zh) 2008-09-02 2013-08-14 Omj制药公司 作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
CA2760741C (fr) 2009-05-12 2018-05-01 Addex Pharma S.A. Derives de 1,2,3-triazolo[4,3-a]pyridine et leur utilisation pour le traitement ou la prevention de troubles neurologiques et psychiatriques
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
AU2011328195B2 (en) 2010-11-08 2015-04-02 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
KR102502485B1 (ko) 2014-01-21 2023-02-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
SG10201913625XA (en) 2015-08-07 2020-03-30 Imaginab Inc Antigen binding constructs to target molecules
WO2018147960A1 (fr) 2017-02-08 2018-08-16 Imaginab, Inc. Séquences d'extension pour dianticorps
KR20190142775A (ko) 2017-04-19 2019-12-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 조작된 항원 수용체를 발현하는 면역 세포

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829583A (en) * 1971-02-20 1974-08-13 Hayashibara Ken Mixture of maltobionic acid and monosodium glutamate as a food seasoning
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5177011A (en) * 1988-08-18 1993-01-05 Calgene, Inc. Plant elongation factor promoters, coding sequences and uses
JP2944721B2 (ja) * 1990-08-22 1999-09-06 生化学工業株式会社 エンドトキシンの測定剤
NZ240921A (en) * 1990-12-12 1994-06-27 Zymogenetics Inc G protein coupled glutamate receptor (neurotransmitters), recombinant production
ES2256370T3 (es) * 1991-08-23 2006-07-16 Nps Pharmaceuticals, Inc. Moleculas activas para el receptor de calcio.
ES2218531T3 (es) * 1991-08-23 2004-11-16 Nps Pharmaceuticals, Inc. Arilalquilaminas activas sobre los receptores del calcio.
IL105587A0 (en) * 1992-05-08 1993-09-22 Lilly Co Eli Human metabotropic glutamate receptor and related dna compounds
AU687736B2 (en) * 1992-05-11 1998-03-05 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
ATE522610T1 (de) * 1993-09-20 2011-09-15 Novartis Pharma Gmbh Menschliche, metabotrope glutamatrezeptor- subtypen (hmr6) und verwandte dns-verbindungen
US6274330B1 (en) * 1993-12-30 2001-08-14 Zymogenetics, Inc. L-AP4 sensitive glutamate receptors
JPH10500299A (ja) * 1994-05-16 1998-01-13 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 神経伝達物質輸送体
AU710128B2 (en) * 1995-07-26 1999-09-16 Astrazeneca Ab Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases

Also Published As

Publication number Publication date
ATE369385T1 (de) 2007-08-15
US6077675A (en) 2000-06-20
WO1997048724A3 (fr) 1998-03-26
IL125711A (en) 2006-09-05
EP0882065B1 (fr) 2007-08-08
AU719841B2 (en) 2000-05-18
US6051688A (en) 2000-04-18
ES2292193T3 (es) 2008-03-01
AU3715697A (en) 1998-01-07
US6084084A (en) 2000-07-04
JP2000506392A (ja) 2000-05-30
EP0882065A2 (fr) 1998-12-09
DE69737990D1 (de) 2007-09-20
DE69737990T2 (de) 2008-09-11
CA2246751A1 (fr) 1997-12-24
WO1997048724A2 (fr) 1997-12-24

Similar Documents

Publication Publication Date Title
IL125711A0 (en) Human metabotropic glutamate receptor
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
NO985975L (no) Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
PL314300A1 (en) Peptide-type compounds and their therapeutic application as inhibitors of metalloproteinases
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
AU6602296A (en) Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
CA2165824A1 (fr) Utilisation du modafinil pour la fabrication d'un medicament ayant un effet sur les apnees du sommeil et les troubles ventilatoires d'origine centrale
ATE403672T1 (de) Oral aktive fraktion der momordica charantia, ihre aktiven peptide und ihre verwendung bei der behandlung des diabetes
AU3376297A (en) Human thyrotropin receptor compositions and use thereof
NZ314839A (en) 1,25-Dihydroxy-16,23Z-diene-20-epi-16-ene-cholecalciferol (Vitamin D3) analogues
DE69738613D1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
AU3414295A (en) Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
ZA952086B (en) Heterocyclic compounds their preparation and use
ZA200107283B (en) Vascular adhesion molecules and modulation of their function.
EP0322226A3 (en) Site-directed mutagenesis modified glycoprotein hormones and methods of use
GR3006815T3 (fr)
AU3476595A (en) Use of 2,4-diamino pyrimidine 3-oxide or a salt thereof for treating collagen maturation and structuring disorders
AU5732190A (en) Glycoprotein hormone receptor molecules
DE3681581D1 (de) 4-(1,2,5,6-tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamine und 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamine.
WO2001094414A3 (fr) Sous-unites beta-1a humaines du canal sodium electriquement potentialise et procedes d'utilisation
AP2000002004A0 (en) Method of treatment for dermatological disorders and compositions therefor.
NZ328915A (en) use of sulbutiamine to treat psychomotor and psychointellectual disorders
王殿洪 et al. PURIFICATION AND CHARACTERIZATION OF INSULIN RECEPTORS FROM HUMAN PLACENTA

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed